Meeder Asset Management Inc. Purchases 35,311 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Meeder Asset Management Inc. increased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 49,043.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,383 shares of the company’s stock after purchasing an additional 35,311 shares during the quarter. Meeder Asset Management Inc.’s holdings in Hims & Hers Health were worth $1,046,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Allworth Financial LP grew its stake in Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock worth $56,000 after purchasing an additional 334 shares in the last quarter. Signaturefd LLC grew its stake in Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after purchasing an additional 388 shares in the last quarter. Larson Financial Group LLC grew its stake in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after purchasing an additional 458 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in Hims & Hers Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after purchasing an additional 628 shares in the last quarter. Finally, Cim LLC grew its stake in Hims & Hers Health by 1.0% in the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after purchasing an additional 694 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling

In related news, insider Michael Chi sold 17,102 shares of the firm’s stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the transaction, the insider owned 278,654 shares in the company, valued at $16,649,576.50. This trade represents a 5.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 23,107 shares of the business’s stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the transaction, the chief financial officer owned 63,222 shares of the company’s stock, valued at $2,987,239.50. This represents a 26.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 737,704 shares of company stock worth $40,644,035 in the last 90 days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 2.8%

Shares of HIMS opened at $60.29 on Wednesday. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The stock has a fifty day moving average price of $53.06 and a 200-day moving average price of $43.35. The firm has a market cap of $13.50 billion, a PE ratio of 87.38, a P/E/G ratio of 2.16 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business’s revenue for the quarter was up 110.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.05 EPS. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

HIMS has been the topic of several research analyst reports. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Morgan Stanley reaffirmed an “equal weight” rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. TD Cowen cut Hims & Hers Health from a “buy” rating to a “hold” rating and dropped their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $39.83.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.